(Q36895994)

16 August 2017

1 reference

title

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy (English)

1 reference

16 August 2017

1 reference

Per Soelberg Sørensen

series ordinal

2

object named as

P S Sørensen

1 reference

16 August 2017

D Hesse

1

1 reference

16 August 2017

publication date

1 August 2007

1 reference

European Journal of Neurology

16 August 2017

published in

1 reference

16 August 2017

volume

14

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

850-859

1 reference

The immunogenicity of biopharmaceuticals

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Interspecific allometry of the brain and brain regions in parrots (psittaciformes): comparisons with other birds and primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01769.X

10.1111/J.1468-1331.2007.01769.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference